Comment: Fundamentals and Innovation in Antibiotic Trials

Statistics in Biopharmaceutical Research

Volumn 7, Issue 4, 2015, Pages 331-336

  Evans, Scott R ^a   Follmann, Dean ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CONTROLLED CLINICAL TRIAL (TOPIC); HUMAN; MATHEMATICAL ANALYSIS; MORTALITY; NOTE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84950318090     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2015.1094406     Document Type: Note

References (33)

1. AIDAC (2012), Capital Reporting Company. Anti-Infective Drugs Advisory Committee (AIDAC) Meeting 29 November 2012, available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM340465.pdf
2. J.Couzin-Frankel, (2015), “Clinical Trials Get Practical,” Science, 348, 382.
3. E.Cox,, L.Borio,, and R.Temple, (2014), “Evaluating Ebola Therapies —-The Case for RCTs,” New England Journal of Medicine, 371, 2350–2351.
4. R.B.D’Agostino, J.M.Massaro, and L.M.Sullivan,. (2003), “Non-Inferiority Trials: Design Concepts and Issues—The Encounters of Academic Consultants in Statistics,” Statistics in Medicine, 22, 169–86.
5. L.E.Dodd,, M.A.Proschan,, J.Neuhaus,, J.Koopmeiners,, J.Neaton,, J.D.Beigel,, K.Barrett,, H.C.Lane,, and R.T.Davey, (2015), “Design of a Randomized Controlled-Trial for Ebola Virus Disease Medical Countermeasures: The Ebola MCM Study,” unpublished manuscript.
6. S.R.Evans, (2009), “Noninferiority Clinical Trials,” Chance, 22, 53–8.
7. ——— (2010), “Estudos Clinicos de Nao-Inferioridade,” Revista Brasileira de Medicina, 67, 7.
8. S.R.Evans,, D.Rubin,, D.Follmann,, G.Pennello,, W.C.Huskins,, J.H.Powers,, D.Schoenfeld,, C.Chuang-Stein,, S.E.Cosgrove,, V.G.FowlerJr.,, E.Lautenbach,, and H.F.Chambers, (2015), “Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR),” CID, 61, 800–806.
9. FDA (2013), “Guidance for Industry Acute Skin and Skin Structure Infections: Developing Drugs for Treatment,” available at http://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf
10. M.E.Falagas, and S.K.Kasiakoum, (2005), “Colistin: The Revival of Polymyxins for the Management of Multidrug-Resistant Gram-negative Bacterial Infections,” Clinical Infectious Diseases, 40, 1333–1341.
11. M.E.Falagas,, G.S.Tansarli,, D.E.Karageorgopoulos,, and K.Z.Vardakas, (2014), “Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections,” Emerging Infectious Diseases, 20, 1170--1175.
12. M.E.Flacco,, L.Manzolia,, S.Boccia,, L.Capasso,, K.Aleksovska,, A.Rosso,, G.Scaioli,, C.De Vitoe,, R.Siliquinif,, P.Villarie,, and J.P.A.Ioannidis, (2015), “Head-to-Head Randomized Trials Are Mostly Industry Sponsored and Almost Always Favor the Industry Sponsor,” Journal of Clinical Epidemiology, 68, 811–820.
13. T.R.Fleming, (2008), “Current Issues in Non-Inferiority Trials,” Statistics in Medicine 27, 317–32.
14. P.Gao,, and J.H.Ware, (2008), “Assessing Non-Inferiority: A Combination Approach,” Statistics in Medicine, 27, 392–406.
15. E.A.Gehan, (1984), “The Evaluation of Therapies: Historical Control Studies,” Statistics in Medicine, 3, 315–324.
16. T.Hamasaki,, and S.R.Evans, (2013), “Noninferiority Clinical Trials: Issues in Design, Monitoring, Analyses, and Reporting,” Igaku no Ayumi, 244, 1212–1216.
17. J.D.Hartzell,, Neff, R., Ake, J., Howard, R., Olson, S., Paolino, K., Vishnepolsky, M., Weintrob, A., and Wortmann, G. (2009), “Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center,” Clinical Infectious Diseases, 48, 1724–1728.
18. International Conference on Harmonization (ICH)-E10 (2000), “Choice of Control Group and Related Issues in Clinical Trials,” available at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf.
19. J.K.Koch-Weser,, Sidel, V. W., Federman, E. B., Kanarek, P., Finer, D. C., and Eaton, A. E. (1970), “Adverse Effects of Sodium Colistimethate: Manifestations and Specific Reaction Rates During 317 Courses of Therapy,” Annals of Internal Medicine, 72, 857–868.
20. R.M.Krause, (1981), The Restless Tide: The Persistent Challenge of the Microbial World, Washington, DC: The National Foundation for Infectious Diseases.
21. M.Lee,, J.Lee,, M.W.Carroll,, H.Choi,, S.Min,, T.Song,, L.Via,, L.Goldfeder,, F.Kang,, B.Jin,, H.Park,, H.Kwak,, H.Kim,, S.Jeon,, I.Jeong,, J.Joh,, R.Chen,, K.Olivier,, P.Shaw,, D.A.Follmann,, S.Song,, J.K.Lee,, D.Lee,, C.Kim,, V.Dartois,, S.Park,, S.Cho,, and C.Barry, (2012), “Linezolid for the Treatment of Chronic Extensively Drug-Resistant Tuberculosis,” New England Journal of Medicine, 367, 1508–1518.
22. Y.Li,, Y.He,, Y.Sheng,, Wang, K., Wang, J., Huang, J., Yang, J., and Zheng, Q. (2013), “Systematic Evaluation of Non-Inferiority and Equivalence Randomized Trials of Anti-Infective Drugs,” Expert Review AntiInfectios Therapy, 11, 1377–89.
23. J.Molina,, and J.M.Cisneros, (2015), “A Chance to Change the Paradigm of Outcome Assessment of Antimicrobial Stewardship Programs,” CID, 61, 807–808.
24. J.Neaton,, Gray, G., Zuckerman, B. D., and Konstam, M. A. (2005), “Key Issues in End Point Selection for Heart Failure Trials: Composite Endpoints,” Journal of Cardiac Failure, 11, 567–575.
25. M.Paul, Bishara, J., Levcovich, A., Chowers, M., Goldberg, E., Singer, P., Lev, S., Leon, P., Raskin, M., Yahav, D., and Leibovici, L. (2010), “Effectiveness and Safety of Colistin: Prospective Comparative Cohort Study,” Journal of Antimicrobial Chemotherapy, 65, 1019–1027.
26. J.H.Powers, (2008). “Noninferiority and Equivalence Trials: Deciphering ‘Similarity’ of Medical Interventions,” Statistics in Medicine, 27, 343–52.
27. J.H.Powers,, C.K.Cooper,, D.Lin,, and D.B.Ross, (2005), “Sample Size and the Ethics of Non-Inferiority Trials,” Lancet, 366, 24–5.
28. Rosenberger, L. H., Lapper, D. J., and Sawyer, R. G.2012“Infections Caused by Multidrug Resistant Organisms are Not Associated with Overall, All-Cause Mortality in the Surgical Intensive Care Unit: The 20,000 Foot View,” Journal of the American College of Surgeons, 214, 747--755.
29. Sacks, H., Chalmers, T. C., and Smith, H.1982“Randomized versus Historical Controls for Clinical Trials,” The American Journal of Medicine, 72, 233--240.
30. S.M.Snappin, (2000), “Noninferiority Trials,” Current Controlled Trials in Cardiovascular Medicine, 1, 19–21.
31. T.Sozu,, T.Sugimoto,, T.Hamasaki,, and S.R.Evans, (2015), Sample Size Determination in Clinical Trials with Multiple Endpoints, New York: Springer.
32. United States Government Accountability Office (2010), Report to Congressional Requesters. New Drug Approval: FDA's Consideration of Evidence from Certain Clinical Trials,. available at http://www.gao.gov/assets/310/308301.pdf.
33. E.Wolinsky,, and J.D.Hines, (1962), “Neurotoxic and Nephrotoxic Effects of Colistin in Patients with Renal Disease,” The New England Journal of Medicine, 266, 759–762.